Oral arsenic trioxide incorporation into frontline treatment with all‐trans retinoic acid and chemotherapy in newly diagnosed acute promyelocytic leukemia: A 5‐year prospective study
暂无分享,去创建一个
C. Kumana | Y. Kwong | R. Leung | C. Lam | S. Yip | H. Gill | R. Wong | Chi-chung Chan | Y. Hwang | C. Lau | J. S. Lau | T. Chan | Rita Yim | Bonnie Kho | V. Mak | Harold-Kwok Lee | Wa Li | H. Ip | Shek-Yin Lin
[1] Xiao-jun Huang,et al. Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial. , 2018, The Lancet. Oncology.
[2] C. Kumana,et al. Long‐term outcome of relapsed acute promyelocytic leukemia treated with oral arsenic trioxide‐based reinduction and maintenance regimens: A 15‐year prospective study , 2018, Cancer.
[3] E. Estey,et al. Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. , 2017, Blood.
[4] N. Schmitz,et al. Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] R. Hills,et al. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. , 2015, The Lancet. Oncology.
[6] P. Kligfield,et al. Prevalence, management, and clinical consequences of QT interval prolongation during treatment with arsenic trioxide. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] Paola Fazi,et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. , 2013, The New England journal of medicine.
[8] J. Reynolds,et al. All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). , 2012, Blood.
[9] S. Lok,et al. Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation. , 2012, Blood.
[10] W. Au,et al. Oral arsenic trioxide for relapsed acute promyelocytic leukemia in pediatric patients , 2012, Pediatric blood & cancer.
[11] Joseph O. Deasy,et al. Common Terminology Criteria for Adverse Events (CTCAE) v4.0 Based Hybrid Patient and Physician Questionnaire for Head and Neck (HN) Radiotherapy Symptom Reporting , 2011 .
[12] R. Larson,et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. , 2010, Blood.
[13] M. Vignetti,et al. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. , 2010, Blood.
[14] M. Tallman,et al. How I treat acute promyelocytic leukemia. , 2009, Blood.
[15] W. Hiddemann,et al. High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG , 2009, Leukemia.
[16] H. Dombret,et al. Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group experience. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] Jiong Hu,et al. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia , 2009, Proceedings of the National Academy of Sciences.
[18] C. Lau,et al. Effects of oral arsenic trioxide therapy on QT intervals in patients with acute promyelocytic leukemia: implications for long-term cardiac safety. , 2006, Blood.
[19] C. Kumana,et al. Oral arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia. , 2003, Blood.
[20] C. Bloomfield,et al. CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol , 2022 .
[21] Y. Kwong,et al. Systemic availability of arsenic from oral arsenic-trioxide used to treat patients with hematological malignancies , 2002, European Journal of Clinical Pharmacology.
[22] S. Soignet,et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] Mark Payne,et al. Health and Human Services , 2020, Congress and the Nation 2013-2016, Volume XIV: Politics and Policy in the 113th and 114th Congresses.
[24] C. Kumana,et al. Oral arsenic trioxide – based maintenance regimens for first complete remission of acute promyelocytic leukemia : a 10-year follow-up study , 2011 .
[25] S J Chen,et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. , 1999, Blood.